Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition
Innovative strategies are necessary to maximize the clinical application of HIV neutralizing antibodies. To this end, bispecific constructs of human antibody F240, reactive with well-conserved gp41 epitope and antibody 14A8, reactive with the IgA receptor (CD89) on effector cells, were constructed....
Main Authors: | Xiaocong Yu, Mark Duval, Melissa Gawron, Marshall R. Posner, Lisa A. Cavacini |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2016/9425172 |
Similar Items
-
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
by: Jim Middelburg, et al.
Published: (2021-01-01) -
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
by: Bingyu Li, et al.
Published: (2018-01-01) -
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
by: Brian Alexander, et al.
Published: (2020-07-01) -
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
by: Andres Lopez-Albaitero, et al.
Published: (2017-03-01) -
The development of bispecific monoclonal antibodies for therapy
by: Gilliland, Lisa Kim
Published: (1987)